anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: A novel risk scoring system, predicated on DNA damage response (DDR), was developed to enhance prognostic predictions and potentially inform the creation of more effective therapeutic protocols for sepsis.
METHODS: To thoroughly delineate the expression profiles of DDR markers within the context of sepsis, an analytical approach utilizing single-cell RNA-sequencing (scRNA-seq) was implemented. Our study utilized single-cell analysis techniques alongside weighted gene co-expression network analysis (WGCNA) to pinpoint the genes that exhibit the most substantial associations with DNA damage response (DDR). Through Cox proportional hazards LASSO regression, we distinguished DDR-associated genes and established a risk model, enabling the stratification of patients into high- and low-risk groups. Subsequently, we carried out an analysis to determine our model's predictive accuracy regarding patient survival. Moreover, we examined the distinct biological characteristics, various signal transduction routes, and immune system responses in sepsis patients, considering different risk categories and outcomes related to survival. Lastly, we conducted experimental validation of the identified genes through in vivo and in vitro assays, employing RT-PCR, ELISA, and flow cytometry.
RESULTS: Both single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic analyses have demonstrated a strong correlation between DNA damage response (DDR) levels and sepsis prognosis. Specific cell subtypes, including monocytes, megakaryocytes, CD4+ T cells, and neutrophils, have shown elevated DDR activity. Cells with increased DDR scores exhibited more robust and numerous interactions with other cell populations. The weighted gene co-expression network analysis (WGCNA) and single-cell analyses revealed 71 DDR-associated genes. We developed a four-gene risk scoring system using ARL4C, CD247, RPL7, and RPL31, identified through univariate COX, LASSO COX regression, and log-rank (Mantel-Cox) tests. Nomograms, calibration plots, and decision curve analyses (DCA) regarding these specific genes have provided significant clinical benefits for individuals diagnosed with sepsis. The study suggested that individuals categorized as lower-risk demonstrated enhanced infiltration of immune cells, upregulated expression of immune regulators, and a more prolific presence of immune-associated functionalities and pathways. RT-qPCR analyses on a sepsis rat model revealed differential gene expression predominantly in the four targeted genes. Furthermore, ARL4C knockdown in sepsis model in vivo and vitro caused increased inflammatory response and a worse prognosis.
CONCLUSION: The delineated DDR expression landscape offers insights into sepsis pathogenesis, whilst our riskScore model, based on a robust four-gene signature, could underpin personalized sepsis treatment strategies.
Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
FIELD: medicine. ^ SUBSTANCE: invention is referred to the method of electrochemical teeth whitening which consists of putting on the teeth first the solution of salt of transition metal and then oxidizing agent while limiting the effect of metal salts and oxidizing agent on non-dental oral tissues. After that positive and negative electrodes are configured in oral cavity in such a way that negatively charged electrodes contact with teeth and electric current is sent only in oral cavity to said oxidizing agent for its activation and reduction. Oxidizing agent contains hydrogen peroxide, solution or gel of carbamide peroxide or sodium perborate. The invention is also referred to teeth whitening device that contains applicator suitable for putting salt of transition metal and oxidizing agent on teeth. Applicator is made in shape of dental tray and has first and second ends to which the electrodes are connected with the possibility of sending electric current through the applicator as well as sealing bulge for limiting the oxidizing agent effect on non-dental oral tissue. The group of inventions provides for regulation of safe application, supply and distribution on teeth of oxidizing agent. ^ EFFECT: simple and safe method of teeth whitening; minimal effect of oxidizing agent on non-dental oral tissue. ^ 31 cl, 7 dwg, 1 tbl, 1 ex
Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.
The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
This is a study to measure specific proteins in the cerebral spinal fluid (CSF) of healthy elderly volunteers and volunteers with mild cognitive impairment (MCI) or Alzheimer's Disease (AD). No investigational medical drug will be given to volunteers during their participation in this study. Healthy elderly volunteers will be enrolled in Part A of the study and will be randomized (assigned by chance) to 1 of 4 cohorts (groups); each cohort of volunteers will undergo a different type of CSF sampling procedure (a standard frequent CSF sampling procedure, an alternative frequency of CSF sampling procedure, or the standard frequent CSF sampling procedure with 800 mg ibuprofen administered to volunteers on Day 1, or an alternative lower frequency of CSF sampling in comparison to Cohort 1) and will have blood samples collected. Volunteers with MCI or AD will be enrolled in Part B of the study and will undergo 1 CSF sampling procedure (ie, the standard frequent CSF sampling procedure). In addition, all volunteers enrolled who consent (agree) to the pharmacogenomic component of the study, will have a blood sample collected that will allow for genetic research to help understand the link between Alzheimer's Disease biomarker profiles and specific genotypes and to have their DNA samples stored for future genetic research related to CSF proteins and Alzheimer's Disease. Participation in the pharmacogenomic research is optional for volunteers enrolled in Part A Cohort 1 to 3 but required for volunteers enrolled in Part A Cohort 5 and Part B. Participation in the DNA storage component is optional and refusal to participate will not result in ineligibility for the main part of the study. There will be no blinding in this study (ie, volunteers will know the CSF sampling procedure being performed on them). CSF and blood samples will be collected over a period of 36 hours and the maximum duration of the study will be no more than 6 weeks. During the study, volunteers will be monitored to evaluate the safety and tolerability of the CSF sampling procedures.
5.1 Risk of Life-Threatening Overdose During Pump Refills

Use extreme caution when filling the Medtronic SynchroMed® II Programmable Pump which is equipped with an injection port that allows direct access to the intrathecal catheter. Direct injection into the catheter through the catheter access port may cause a life-threatening overdose.

Reservoir refilling must be performed by fully trained and qualified personnel following the directions provided by the pump manufacturer. Carefully calculate refill intervals to prevent depletion of the reservoir, as this would result in the return of severe spasticity and possibly symptoms of withdrawal.

Strict aseptic technique in filling is required to avoid bacterial contamination and serious infection. A period of observation appropriate to the clinical situation should follow each refill or manipulation of the drug reservoir.
PURPOSE:To obtain a constituent component for the membrane of a small closed cell, having a cationic membrane material and a hydrophilic polymer derivative in one molecule and containing a hydrophobic region, and a medical carrier including a medicine for diagnosing and improving an injured part of the vascular endothelium therein. CONSTITUTION:This constituent component for the membrane of a small closed cell has a cationic hydrophilic region composed of a hydrophilic region having one or more cationic residues and one or more hydroxyl groups at one end of one molecule, a hydrophobic region at the other end and a hydrophilic polymer chain region in a section between the cationic hydrophilic region and the hydrophobic region and/or ahead the cationic hydrophilic region. The medical carrier contains this constituent component for the membrane of a small closed cell and includes a medicine for diagnosing and improving an injured part of the vascular endothelium therein. As the constituent component, e.g. N-palmitoyl-3-[(3-aminopropoxy)-poly(oxyethylene)]propylamine of formula I and the compound of formula II are exemplified. The medical carrier containing this constituent component for the membrane of a small closed cell is excellent in inclusion ratio of a neutral or anionic substance and also in safety.
Dengue viruses cause dengue fever and the more severe dengue hemorrhagic fever/shock syndrome. More than 2 billion people living in tropical and subtropical regions of the world are at risk of dengue virus infection, which is the leading cause of hospitalization and death in children in several tropical Asian countries. This study will evaluate the safety and immunogenicity of a live attenuated dengue virus vaccine called rDEN4delta30-200,201. This vaccine is derived from rDEN4delta30, another dengue virus vaccine candidate that has been shown to be safe and immunogenic in Phase I and II trials in healthy adults.

This study will last 180 days. There will be three cohorts in this dose de-escalation study. Participants in Cohort 1 will be randomly assigned to receive the highest dose of rDEN4delta30-200,201 or placebo at study entry. Cohort 2 will begin only after safety review of all participants in Cohort 1. Participants in Cohort 2 will receive a lower dose of rDEN4delta30-200,201 or placebo. Cohort 3 will begin only after safety review of all participants in Cohort 2. Participants in Cohort 3 will receive the lowest dose of rDEN4delta30-200,201 or placebo.

After vaccination, participants will be asked to monitor their temperatures every day for 16 days. Study visits will occur every other day after vaccination until Day 16, followed by four additional visits at selected days through Day 180. Blood collection, vital signs measurement, and a targeted physical exam will occur at each study visit. Some participants will be asked to undergo a skin biopsy or additional blood collection at selected visits.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to the pharmaceutical industry, in particular to the use of a collagen hydrolysate for the treatment of sarcopenia. Use of collagen hydrolysate as an active ingredient for the treatment of sarcopenia, wherein the collagen hydrolysate does not contain any free amino acids added to thereto and has an average molecular weight of up to 5,000 Da. Use of collagen hydrolysate as an active substance against degenerative muscle loss and for improving muscle strength. Use of collagen hydrolysate as an active ingredient for reducing age-related muscle loss. Use of collagen hydrolysate as an active ingredient for stimulating the conversion of body fat into muscle mass. Method for the treatment of sarcopenia, which comprises repeated oral administration of collagen hydrolysate to a patient in combination with muscle exercise.EFFECT: above-described collagen hydrolysate effectively increases muscle mass, reduces fat mass and metabolic cost.19 cl, 2 dwg, 1 ex
Postoperative cognitive dysfunction (POCD) is one of the most common complications in patients undergoing cardiac surgery. POCD will not only increase the incidence of complications and mortality, but also influence the quality of life after discharging from the hospital. Many factors are associated with POCD, such as neuroinflammation, age, anesthetics, surgery stress response and genetic factors. But the underlying mechanisms are still unclear. Blood Oxygen Level Dependent (BOLD) fMRI, which could monitor the peripheral neuron spontaneous activity according to the ratio of oxyhemoglobin and deaeration hemoglobin in blood, will be used to investigate whether POCD is induced by the variance in neurons metabolism and spontaneous activity in brain regions. Meanwhile, biochemical indicators will be detected to explore the prompting indicators of POCD. The present study is aimed to represent a promising precursory target for diagnosis and treatment of POCD, and provide novel evidence and insights on the brain changes induced by POCD.
ETHNOPHARMACOLOGICAL RELEVANCE: Anoectochilusroxburghii (Wall.) Lindl. (AR), as an exceptionally valuable traditional Chinese medicine, has been widely used to treat hepatitis, cancer, diabetes, etc. But, the effects and the primary functioning element of AR on attenuating aging and aging-related learning and memory degradation has not yet been explored.
AIM OF THE STUDY: This study aimed at exploring the protective property of aqueous extract of AR (AEAR) on alleviation of aging and aging-related learning and memory impairment in vivo, and further investigating the main active ingredient and mechanism of AEAR.
MATERIALS AND METHODS: D-galactose (D-gal) induced aging mice and HT22 cells exposed with L-Glutamic acid (Glu) were used as in vivo and in vitro model, separately. The effects of AEAR on aging and aging-related learning and memory degradation were explored by using morris water maze test, immunohistochemistry staining, biochemistry assay, etc. The effects and mechanism of AEAR and Kinsenoside (Kin) on antioxidation in vitro were investigated by cell viability assay, biochemistry assay, qRT-PCR, western blotting and molecular docking studies.
RESULTS: Treatment with AEAR (containing 69.52 ± 0.85% Kin, i.g.) for 63 days, alleviated low growth rate, abnormal brain, liver and thymus index, and decline in learning and memory capability of aging mice. Meanwhile, AEAR inhibited the decreased activities of SOD and GSH-PX, the decline in the ratio of GSH to GSSG, and the increase of MDA in both serum and brain, and also promoted the Nrf2 nuclear translocation in brain of aging mice induced by D-gal. The effects of AEAR on alleviating abnormal physiological characteristics, attenuating learning and memory impairment, and inhibiting oxidative stress in aging mice was similar to or even better than that of Vc. In HT22 cells exposed with Glu, Kin increased the cell viability, up-regulated the activities of SOD and GSH-PX, enhanced the ratio of GSH to GSSG, and down-regulated MDA, which was superior to AEAR. Kin up-regulated the ratio of p-ERK1/2 to ERK1/2, promoted the Nrf2 nuclear translocation and its downstream target genes, i.e. HO-1, NQO-1, GCLC and GCLM expression at the mRNA and protein levels, which were consistent with AEAR. Further, molecular docking results also confirmed that Kin had strong binding energy with ERK1 and ERK2.
CONCLUSION: The present study indicated that Kin could alleviate the oxidative stress in aging mice via activating the ERK/Nrf2 signaling pathway, in order to attenuate aging and aging-related learning and memory impairment, as the main active ingredient of AR.
Aspects for utilizing a seawater fluid to optimize egg-production characteristics are disclosed. In one aspect, a method is provided, which includes identifying a desired optimization, determining a corresponding seawater to non-seawater ratio, and generating a seawater fluid according to the ratio. An egg-cultivation method is also provided, which includes ascertaining a desired optimization, selecting a corresponding seawater to non-seawater ratio, and providing a seawater fluid comprising the ratio to a hen. In another egg-cultivation method, hens are provided with a mixed feed comprising a feed to seawater-mineralized produce ratio selected according to a desired optimization. A method to grow produce is also provided, which includes mineralizing soil with a seawater fluid comprising a seawater to non-seawater ratio corresponding to a preferred optimization. In another aspect, a method to produce feed is disclosed, which includes mixing feed with mineralized produce according to a ratio corresponding to a desired optimization.
PURPOSE:To provide the titled ceramic material composed of a ceramic material attached to a substrate sheet such as Japanese paper, plastic sheet, etc. having a specific thickness, and capable of forming a beautiful opaque layer having uniform thickness without necessitating skilled labor, only by pressing the composite sheet to the surface of a dental crown material, and baking the material. CONSTITUTION:Ceramic powder such as opaque powder is supplied from the tank 1, kneaded with water or an organic solvent to obtain the slurry 2, and stored in the slurry tank 3. The slurry 2 is applied to one surface of the substrate sheet S composed of an organic material such as Japanese paper, plastic sheet, etc. having a thickness of <=1mm. (preferably about 0.5mm.) and delivered along the direction of the arrow by the rotation of the roller 4. The substrate applied with the ceramic slurry is if necessary passed through the vibration or pressing roll 7 to obtain a ceramic sheet T composed of the ceramic material C laminated to the substrate sheet at a thickness of 0.01-1.0mm.. The ceramic material T is cut to a shape sufficient to cover the whole circumference of the dental crown material D, attached to the surface of the material D and pressed closely to the surface of the crown material D. The sheet S is released from the product leaving the ceramic C on the surface of the dental corwn, and the ceramic C is baked to obtain the objective dental crown.
The invention concerns neuro:transmitter co-transporter membrane protein 13 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes neuro:transmitter co-transporter membrane protein 13.
In Study 1 [see Clinical Studies (14)], the pharmacological effect of efgartigimod alfa-fcab was assessed by measuring the decrease in serum IgG levels and AChR autoantibody levels. In patients testing positive for AChR antibodies and who were treated with efgartigimod alfa-fcab intravenous, there was a reduction in total IgG levels relative to baseline. Decrease in AChR autoantibody levels followed a similar pattern. A decrease in AChR-Ab was associated with a clinical response in AChR-Ab positive patients, as measured by the change from baseline in MG-ADL total score.

In Study 2, the pharmacological effect of VYVGART HYTRULO administered subcutaneously (SC) at 1,008 mg / 11,200 Units was compared to efgartigimod alfa-fcab administered intravenously at 10 mg/kg (EFG IV) in gMG patients. The maximum mean reduction in AChR-Ab level was observed at week 4, with a mean reduction of 62.2% and 59.7% in the VYVGART HYTRULO SC and efgartigimod alfa-fcab IV arm, respectively. The decrease in total IgG levels followed a similar pattern. The 90% confidence intervals for the geometric mean ratios of AChR-Ab reduction at day 29 and AUEC0-4w (area under the effect-time curve from time 0 to 4 weeks post dose) were within the range of 80% to 125%, indicating no clinically significant difference between the two formulations.
Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
PURPOSE:To obtain a carcinostatic agent, by adding a compound having carcinostatic action and a growth factor, a peptide corresponding to part of the constituent component of the growth factor, a derivative or a salt thereof as active ingredients. CONSTITUTION:A carcinostatic agent containing a compound (e.g. alkylating agent such as cyclophosphamide, antimetabolite such as 5-fluorouracil, etc., antibiotic such as mitomycin, etc., platinum preparation) and a growth factor (e.g. epidermal growth factor such as hEGF, etc., insulin group, growth factor group derived from blood platelet, etc.), a peptide corresponding to part of the constituent component of the growth factor, a derivative or a salt thereof as active ingredients. The dosage form may be oral or parenteral and optionally may be blended with other drug. A dose is preferably 10ng-10mg/person/day. A carcinostatic agent effective for any of all cancers can be prepared by properly selecting each active component.